Amphastar Pharmaceuticals (NASDAQ:AMPH) Downgraded by TheStreet

TheStreet cut shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a b- rating to a c rating in a research note released on Thursday morning, TheStreetRatingsTable reports.

AMPH has been the topic of several other reports. BidaskClub cut shares of Amphastar Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, October 29th. ValuEngine cut shares of Amphastar Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, September 20th. Finally, Zacks Investment Research cut shares of Amphastar Pharmaceuticals from a buy rating to a hold rating in a research note on Thursday, October 24th. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of $24.44.

AMPH stock traded down $0.71 during mid-day trading on Thursday, reaching $18.41. 600,700 shares of the stock traded hands, compared to its average volume of 195,968. Amphastar Pharmaceuticals has a 52 week low of $16.92 and a 52 week high of $25.43. The company has a quick ratio of 1.83, a current ratio of 2.81 and a debt-to-equity ratio of 0.13. The business has a 50-day moving average of $19.87 and a two-hundred day moving average of $20.65. The firm has a market capitalization of $918.08 million, a PE ratio of 87.67 and a beta of 1.17.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.10 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.08 by $0.02. Amphastar Pharmaceuticals had a net margin of 16.33% and a return on equity of 5.52%. The business had revenue of $80.14 million for the quarter, compared to analysts’ expectations of $78.53 million. During the same period in the prior year, the firm earned $0.12 earnings per share. Amphastar Pharmaceuticals’s revenue was up 6.1% compared to the same quarter last year. On average, equities research analysts anticipate that Amphastar Pharmaceuticals will post 0.17 EPS for the current fiscal year.

In other Amphastar Pharmaceuticals news, CEO Jack Y. Zhang sold 300,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $20.82, for a total value of $6,246,000.00. Following the transaction, the chief executive officer now directly owns 2,147,316 shares of the company’s stock, valued at $44,707,119.12. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, General Counsel Jason B. Shandell sold 7,340 shares of the firm’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $21.32, for a total transaction of $156,488.80. Following the completion of the transaction, the general counsel now directly owns 147,103 shares in the company, valued at $3,136,235.96. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 354,479 shares of company stock worth $7,415,153. Insiders own 30.80% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Prudential Financial Inc. boosted its stake in Amphastar Pharmaceuticals by 1.4% in the second quarter. Prudential Financial Inc. now owns 63,076 shares of the company’s stock valued at $1,331,000 after acquiring an additional 870 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Amphastar Pharmaceuticals by 15.4% in the second quarter. JPMorgan Chase & Co. now owns 9,856 shares of the company’s stock valued at $205,000 after acquiring an additional 1,314 shares during the last quarter. Rhumbline Advisers boosted its stake in Amphastar Pharmaceuticals by 1.3% in the third quarter. Rhumbline Advisers now owns 108,931 shares of the company’s stock valued at $2,160,000 after acquiring an additional 1,358 shares during the last quarter. Swiss National Bank boosted its stake in Amphastar Pharmaceuticals by 2.2% in the second quarter. Swiss National Bank now owns 64,400 shares of the company’s stock valued at $1,359,000 after acquiring an additional 1,400 shares during the last quarter. Finally, Arizona State Retirement System raised its holdings in Amphastar Pharmaceuticals by 2.7% in the second quarter. Arizona State Retirement System now owns 54,756 shares of the company’s stock worth $1,156,000 after purchasing an additional 1,422 shares during the period. 47.21% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Recommended Story: Initial Coin Offerings entail a high degree of risk

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.